Long-term results with the slow-release formulation of lanreotide in acromegalic patients

Journal of Endocrinological Investigation

Volumn 20, Issue 7 SUPPL., 1997, Pages 37-42

  Giusti, M ^a   Arosio, M ^b   Ciccarelli, E ^c   Cuttica, C M ^a   Dallabonzana, D ^d   Delitala, G ^e   Gussoni, G ^a   Liuzzi, A ^f   Giordano, G ^g  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e UNIVERSITY OF SASSARI   (Italy)

^f CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^g IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0343812229     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Tindall G., Oyesiku N., Watts N., Clark R., Christy J., Adams P. Trans-phenoidal adenomectomy for growth hormone-secreting adenomas in acromegaly: outcome analysis and determinants of failure. J. Neurosurg. 78: 205, 1993.
2. Robbins R.J. Editorial: Depot somatostatin analogs - A new first line therapy for acromegaly. J. Clin. Endocrinol. Metab. 82: 15, 1997.
3. Melmed S., Ho K., Klibanski A., Reichlin S., Thorner M. Clinical review 75. Recent advances in pathogenesis, diagnosis, and management of acromegaly. J. Clin. Endocrinol. Metab. 80: 3395, 1995.
4. Stoffel-Wagner B., Springer W., Bidlingmaier F., Klingmuller D. A comparison of different methods for diagnosing acromegaly. Clin. Endocrinol. 46: 531, 1997.
5. Lamberts S.W.J., Van der Lely A.-J., De Herder W.W., Hofland L. Octreotide. N. Engl. J. Med. 334: 246, 1996.
6. Flogstad A.K., Halse J., Bakke S., et al. Sandostatin LAR in acromegalic patients: long term treatment. J. Clin. Endocrinol. Metab. 82: 23, 1997.
7. Heron I., Thomas F., Dero M., et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J. Clin. Endocrinol. Metab. 76: 721, 1993.
8. Frohman L.A. Editorial. Acromegaly: what constitutes optimal therapy? J. Clin. Endocrinol. Metab. 81: 443, 1996.
9. Giusti M., Gussoni G., Cuttica C.M., Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. J. Clin. Endocrinol. Metab. 81: 2089, 1996.
10. Giusti M., Arosio M., Ciccarelli E., et al. Effects of long-term slow-release lanreotide treatment in selected patients with active acromegaly. In: Von Werder K., Fahlbush R. (Eds.), Pituitary adenomas: from basic research to diagnosis and therapy. Elsevier Science B.V., Amsterdam, 1996, p. 55.
11. Giusti M., Ciccarelli E., Dallabonzana D., et al. Clinical results of long term slow-release lanreotide treatment of acromegaly. Eur. J. Clin. Invest. 27: 277, 1997.
12. Marek J., Hana V., Krsek M., Justova V., Catus F., Thomas F. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur. J. Endocrinol. 131: 20, 1994.